White paper
07.2026

NIPPON Genetics EUROPE
INNOVATION FOR YOU

Immediate viability is not enough.
Why functional recovery matters after cryopreservation

A publication-supported perspective on evaluating post-thaw cell quality with Bambanker™ beyond survival alone



Introduction

Cryopreservation is a routine but critical step in cell biology. It allows researchers to preserve valuable cell lines, patient-derived samples, immune cells, stem cells, organoids, and other biological models for future experiments. After thawing, the first question is often simple: are the cells alive?

Immediate post-thaw viability is an important quality check. Low viability can indicate poor handling, unsuitable freezing conditions, or damage during storage and thawing. However, viability alone does not always answer the more important experimental question: are the cells functionally recovered and ready for reliable downstream use?

This distinction matters because cryopreservation can affect cell attachment, proliferation, metabolism, differentiation capacity, immune response, marker expression, morphology, or assay performance. For complex or high-value cell models, successful cryopreservation should therefore mean more than survival. It should mean recovery of the biological characteristics required for the next experiment.

Immediate post-thaw viability is an important first checkpoint, but it does not always confirm experiment readiness. For sensitive or high-value cell models, cryopreservation success should also be evaluated using recovery endpoints that match the intended downstream application.

Why viability became the default metric

Post-thaw viability is widely used because it is fast, familiar, and easy to quantify. Trypan blue exclusion, automated cell counting, fluorescent live/dead stains, and similar methods give researchers an immediate indication of membrane integrity or apparent cell survival.

WHY LABS USE IT

Immediate viability is practical because it is:

- Fast
- Familiar
- Quantifiable
- Easy to compare

WHAT IT TELLS YOU

It gives an early indication of:

- Short-term cell survival
- Membrane integrity
- Acute freeze-thaw damage

WHAT IT MAY MISS

It does not necessarily capture:

- Delayed cell death
- Impaired attachment
- Altered metabolism
- Changed phenotype
- Loss of 3D architecture
- Reduced assay performance

These methods are useful, but they are limited. Most viability assays are not designed to measure whether cells have restored normal metabolism, whether adherent cells can reattach efficiently, whether immune cells can respond to stimulation, or whether stem cells retain the ability to differentiate. They also may not capture delayed injury that becomes visible only after several hours or days in culture.

A broad review of cryopreservation principles and cell-specific considerations emphasizes that both viability and functional assays are important for evaluating post-thaw cell quality. In other words, viability is a necessary checkpoint, but it is not always a sufficient endpoint.

The gap between "alive" and "experiment-ready"

Immediate post-thaw viability is useful, but it does not always predict whether cells will recover the characteristics needed for downstream experiments. Across different cell models, published studies[2-7] show that cells may appear viable or recoverable by basic survival measures, while later or model-specific readouts reveal changes in adhesion, metabolism, immune subset composition, differentiation potential, 3D structure, or assay-relevant function.

MSCs

STUDY MODEL
Human bone marrow-derived MScs.

KEY FINDING
Viability recovered by 24 h post-thaw, but metabolic activity and adhesion potential remained lower than fresh cells.

WHY IT MATTERS
Attachment, expansion, colony-forming ability, and differentiation are central to MSC workflows.

Bahsoun S. *et al.*, 2020

PBMCs/T cells

STUDY MODEL
PBMCs and human peripheral blood T cells.

KEY FINDING
PBMC recovery and viability remained relatively stable, while monocytes and B cells were reduced, T cell subset proportions changed, and activation/regulatory markers were affected.

WHY IT MATTERS
Immune studies depend on subset composition, activation state, and functional response, not only total viable cells.

Li B. *et al.*, 2022; Baboo J. *et al.*, 2019

Kidney organoids

STUDY MODEL
Human pluripotent stem cell-derived kidney organsoids.

KEY FINDING
Cryopreservation quality was assessed using organoid size, growth, nephron-segment preservation, podocyte/tubule structures, inflammatory response, DNA damage, and regenerative capacity after cisplatin injury.

WHY IT MATTERS
Organoid value depends on structural and functional integrity, not only live-cell recovery.

Mashouf P. *et al.*, 2024

iPSC-derived neural cells

STUDY MODEL
Human midbrain dopaminergic neural progenitor cells.

KEY FINDING
Differences between cryopreservation conditions were not apparent immediately after thawing, but became detectable after 24 h of post thaw culture.

WHY IT MATTERS
iPSC-derived workflows depend on recovery, survival, and differentiation potential after thawing.

Drummond N. J. *et al.*, 2020

Liver-cell spheroids

STUDY MODEL
HepG2 liver-cell spheroids.

KEY FINDING
Recovery was measured at 24 h to avoid misleading results from delayed onset apoposis, cytokeletal integrity, cell cycle, doxorbicin response, and CYP3A4 activity were also evaluated.

WHY IT MATTERS
Spheroids used for toxicology or drug testing must retain assay-relevant behavior after thawing.

Bissoyi A. *et al.*, 2023

These examples show why “alive” and “experiment-ready” are not the same endpoint. Immediate viability confirms short-term survival after thawing; functional recovery asks whether cells retain the biological properties required for the intended model, assay, or workflow.

What functional recovery means by cell model

Functional recovery is not a single universal endpoint. The most relevant recovery readouts depend on the biological model, the sensitivity of the cells, and the downstream experiment. A viability assay can indicate whether cells survived the freeze-thaw process, but it does not necessarily show whether the recovered cells retain the properties that made them useful before freezing.

For this reason, functional recovery should be defined in relation to the intended use of the cells. In routine adherent cultures, recovery may focus on attachment, morphology, and proliferation[2]. In immune cell workflows, recovery may depend on preserved subset composition and response to stimulation[3, 4, 12]. In stem cell or iPSC-derived workflows, recovery may require retention of phenotype, maturation state, or differentiation potential[5,9]. In organoids, spheroids, and patient-derived samples, recovery may also depend on 3D architecture, population diversity, molecular profile, or assay performance[6-8,11].

Cell model	Why viability alone may be incomplete	Functional recovery may include
MSCs	Cells may survive thawing but still show impaired attachment, spreading, metabolic activity, or expansion. For MSCs, this matters because attachment, colony-forming ability, and differentiation are often central to downstream use.	Attachment, morphology, spreading, proliferation, metabolic activity, colony-forming ability, differentiation potential
PBMCs/T cells	Overall viability may not reflect changes in immune subset composition, activation state, apoptosis, proliferation, or response to stimulation. This is important when cryopreserved cells are used for immunophenotyping, cytokine assays, activation studies, or functional immune assays.	Subset preservation, activation markers, apoptosis, proliferation after stimulation, cytokine production, suppressive function
iPSC-derived cells	Cells may survive thawing but lose recovery capacity, phenotype, maturation status, or differentiation potential. For iPSC-derived models, the downstream value often depends on whether the cells can continue along the intended lineage or retain model-specific function.	Recovery after 24 h, marker expression, differentiation potential, maturation markers, neurite outgrowth or model-specific morphology, functional assays
Organoids/ spheroids	Viable cells may remain after thawing, but 3D architecture, cell-cell organization, tissue-like morphology, growth behavior, or assay response may be compromised. This matters because 3D models are often used to approximate tissue biology more closely than 2D cultures.	Structural recovery, morphology, regrowth, tissue-specific markers, cell organization, drug-response behavior, toxicology readouts
Patient-derived samples	Viability alone may not show whether patient-specific biology remains usable for profiling, culture initiation, organoid generation, or functional testing. These samples are often limited and high value, so biological usefulness after thawing is the key endpoint.	Culture initiation, molecular profiling, cell population preservation, histological features, genomic consistency, drug-response patterns

In practice, functional recovery should be defined before freezing, based on how the cells will be used after thawing. A post-thaw viability value can confirm short-term survival, but model-specific recovery endpoints determine whether the cells are suitable for the next experiment. This approach also makes cryopreservation evaluation more reproducible because the success criteria are linked to the biological purpose of the recovered material rather than to a single generic viability threshold.

A practical framework

When evaluating cryopreservation success, ask three sequential questions:



This framework helps separate three different levels of post-thaw quality. A sample may pass the first checkpoint by showing acceptable immediate viability, but still require additional recovery or functional testing before it can be considered experiment-ready. The most relevant endpoints should be selected according to the cell model and the planned downstream application.

Bambanker™ cryopreservation media at a glance

Bambanker™ is an FBS-free cryopreservation media developed to support efficient and reproducible cell freezing workflows. Its simplified protocol can reduce the need for serum-containing preparation steps, helping laboratories decrease hands-on handling time, reduce workflow-associated costs, and simplify cryopreservation logistics.

Cryopreservation outcomes are shaped not only by the freezing medium, but also by the workflow used to prepare, freeze, store, and thaw the cells. Conventional or step-wise freezing protocols may require preparing serum-containing freezing mixtures, gradual addition of cryoprotectant, controlled

cooling steps, intermediate handling, or equipment-dependent freezing procedures. These workflows can be appropriate for specific cell types or regulated protocols, but they also increase hands-on time and the number of variables that must be controlled.

Bambanker™ is designed to simplify this process. In standard workflows, cells are suspended in Bambanker™ and frozen, helping reduce handling complexity. Bambanker™ Direct further simplifies freezing by allowing cells to be frozen without washing or centrifugation.

Product	Best for	Key differentiator	When to choose
Bambanker™ Standard	• Majority of cell lines	Versatile medium Broad-use	Default option for routine cell banking
Bambanker™ hRM	• ES (Embryonic Stem Cells) • iPS (induced Pluripotent Stem Cells)	Contains human serum albumin	Animal-component–free approach is preferred
Bambanker™ DMSO Free	• DMSO-sensitive cells	No DMSO	DMSO is undesirable (e.g., protocols minimizing DMSO exposure)
Bambanker™ Direct	• Hybridoma cells • High-throughput (HTP) applications	No centrifugation of cells is required	Time-efficient freezing workflow, especially on high-throughput freezing days

All Bambanker™ types are serum-free, ready-to-use cryopreservation media.

Functional recovery with Bambanker™

Bambanker™ has been used in published workflows where post-thaw performance was assessed beyond immediate viability. These examples are important because they connect cryopreservation success to the biological purpose of the recovered cells: growth, morphology, marker expression, secretion activity, molecular profiling, or *in vivo* function. Because post-thaw outcomes depend on the complete freeze-thaw workflow, these examples should be interpreted as publication-supported use cases rather than universal performance claims for all cell types.

iPSC-derived dopaminergic neurospheres

Hiramatsu S. et al. evaluated cryopreservation of human iPSC-derived dopaminergic neurospheres for clinical application using Bambanker™ hRM together with a Proton Freezer system[9]. As shown in Figure 1, this study is a strong example of functional recovery-focused cryopreservation because the authors evaluated multiple downstream readouts, including dopaminergic marker expression, dopamine secretion, electrophysiological activity, and transplantation outcomes in 6-OHDA-lesioned rats.



Figure 1: Functional recovery of iPSC-derived dopaminergic neurospheres after cryopreservation with Bambanker™.
a) Cryopreserved iPSC-derived dopaminergic neurospheres showed electrophysiological activity and dopamine content in the same range as fresh neurospheres. Spike amplitude was comparable between fresh and cryopreserved spheres, and dopamine levels were maintained after cryopreservation.
*b) After transplantation into 6-OHDA-lesioned rats, fresh and cryopreserved dopaminergic neurospheres reduced abnormal rotational behavior over time compared with the vehicle control. Cryopreserved spheres showed a dose-dependent functional effect, with both tested cryopreserved cell doses contributing to reduced rotations after transplantation. **p < 0.01; ***p < 0.001; ****p < 0.0001*
Modified from Hiramatsu S. et al., 2022.

The cryopreserved neurospheres showed favorable viability after thawing and demonstrated dopaminergic marker expression, dopamine secretion, and electrophysiological activity comparable to fresh spheres. After transplantation, the cryopreserved cells survived, differentiated into mature dopaminergic neurons, and improved abnormal rotational behavior in the rat model. These results show why survival alone would not have been an adequate endpoint for this function-sensitive iPSC-derived model.

Bambanker™ has also been evaluated in cultured human corneal endothelial cells. Okumura and colleagues screened cryopreservation reagents and identified Bambanker™ hRM as suitable for preserving clinical-grade human corneal endothelial cells. In their study, cells cryopreserved with Bambanker™ hRM showed post-thaw growth behavior and cell density comparable to non-preserved control cells after 28 days of culture (Figure 2a). The cells also formed a monolayer sheet-like structure and retained key corneal endothelial markers, including ZO-1, N-cadherin, and Na+/K+-ATPase (Figure 2b, 2c)[10]. This is relevant to functional recovery because the preserved cells needed to maintain not only viability, but also growth, morphology, and phenotype.



Figure 2: Post-thaw recovery of cultured human corneal endothelial cells cryopreserved with Bambanker™ hRM.

a) Cell density after 28 days of culture was comparable between pre-preservation cells, non-preserved control cells, and cells cryopreserved with Bambanker™. The difference between non-preserved control cells and Bambanker™-preserved cells was not statistically significant.

b) Phase-contrast images show that Bambanker™-preserved cells recovered over time in culture and formed a monolayer with morphology comparable to non-preserved control cells by day 28.

c) Immunostaining showed that Bambanker™-preserved cells retained key human corneal endothelial cell markers, including ZO-1, N-cadherin, and Na+/K+-ATPase, with actin staining also shown. n.s. indicates no statistically significant difference.

Modified from Okumura N. et al., 2019.

Patient-derived breast cancer tissue provides another example where post-thaw success depends on preserving material for downstream analysis rather than measuring viability alone. Restivo G. *et al.* used Bambanker™ to slow-freeze primary breast cancer tissue pieces before thawing, enzymatic digestion, and single-cell RNA sequencing[11]. As shown in Figure 3, the recovered tissue supported



Figure 3: Single-cell profiling of patient-derived breast cancer tissue after slow-freezing in Bambanker™.

a) Single-cell clustering identified multiple cell populations, including breast cancer cells, fibroblasts, immune cell subsets, epithelial cells, endothelial cells, melanocytes, and other stromal or immune populations.

b) Marker-expression analysis showed breast cancer-relevant gene-expression patterns across recovered breast cancer cell populations. Together, these panels illustrate that Bambanker™-preserved patient-derived tissue could support downstream single-cell cellular profiling after thawing.

Modified from Restivo G. et al., 2022.

single-cell clustering of multiple breast cancer-associated cell populations, including breast cancer cells, fibroblasts, immune cell subsets, epithelial cells, endothelial cells, and other stromal or immune populations. Marker-expression analysis further showed breast cancer-relevant gene-expression patterns across recovered breast cancer cell populations. This makes the study relevant to functional recovery because the value of the cryopreserved sample was determined by whether it could still support biologically meaningful cellular profiling after thawing.

Conclusion

Immediate post-thaw viability remains an important quality metric in cryopreservation, but it should not be treated as the only definition of success. Published studies across MSCs, PBMCs, T cells, and other systems show that cryopreservation can affect biological characteristics that matter after the viability count is complete[2-4,12].

For modern cell culture workflows, especially those involving immune cells, stem cells, organoids, patient-derived samples, or function-sensitive assays, the more useful question is whether cells are experiment-ready after thawing.

Bambanker™ supports this broader conversation because it has been reported in peer-reviewed workflows across a wide range of cell and sample types, and Bambanker™-specific publications include examples where post-thaw recovery was assessed beyond simple survival. For researchers, the practical takeaway is clear: choose and evaluate cryopreservation workflows based on the recovery endpoints that matter for the next experiment.

References

1. Whaley, D., Damyar, K., Witek, R. P., Mendoza, A., Alexander, M., & Lakey, J. R. T. (2021). Cryopreservation: An overview of principles and cell-specific considerations. Cell Transplantation, 30. https://doi.org/10.1177/0963689721999617
2. Bahsoun, S., Coopman, K., & Akam, E. C. (2020). Quantitative assessment of the impact of cryopreservation on human bone marrow-derived mesenchymal stem cells: up to 24 h post-thaw and beyond. Stem Cell Research & Therapy, 11(1), 540. https://doi.org/10.1186/s13287-020-02054-2
3. Li, B., Yang, C., Jia, G., Liu, Y., Wang, N., Yang, F., Su, R., Shang, Y., & Han, Y. (2022). Comprehensive evaluation of the effects of long-term cryopreservation on peripheral blood mononuclear cells using flow cytometry. BMC Immunology, 23(1), 30. https://doi.org/10.1186/s12865-022-00505-4
4. Baboo, J., Kilbride, P., Delahaye, M., Milne, S., Fonseca, F., Blanco, M., Meneghel, J., Nancekievill, A., Gaddum, N., Morris, G. J., & Pegg, D. E. (2019). The impact of varying cooling and thawing rates on the quality of cryopreserved human peripheral blood T cells. Scientific Reports, 9(1), 3417. https://doi.org/10.1038/s41598-019-39957-x
5. Drummond, N. J., Singh Dolt, K., Canham, M. A., Kilbride, P., Morris, G. J., & Kunath, T. (2020). Cryopreservation of human midbrain dopaminergic neural progenitor cells poised for neuronal differentiation. Frontiers in Cell and Developmental Biology, 8, 578907. https://doi.org/10.3389/fcell.2020.578907
6. Mashouf, P., Tabibzadeh, N., Kuraoka, S., Oishi, H., & Morizane, R. (2024). Cryopreservation of human kidney organoids. Cellular and Molecular Life Sciences, 81(1), 306. https://doi.org/10.1007/s00018-024-05352-7
7. Bissoyi, A., Tomás, R. M. F., Gao, Y., Guo, Q., & Gibson, M. I. (2023). Cryopreservation of liver-cell spheroids with macromolecular cryoprotectants. ACS Applied Materials & Interfaces, 15(2), 2630–2638. https://doi.org/10.1021/acsami.2c18288
8. Chen, P., Zhou, J.-B., Chu, X.-P., Feng, Y.-Y., Zeng, Q.-B., Lei, J.-H., Wong, K.-P., Chan, T.-I., Lam, C.-W., Zhu, W.-L., et al. (2025). Establishing a cryopreserved biobank of living tumor tissues for drug sensitivity testing. Bioactive Materials, 46, 582–596. https://doi.org/10.1016/j.bioactmat.2024.09.008
9. Hiramatsu, S., Morizane, A., Kikuchi, T., Doi, D., Yoshida, K., & Takahashi, J. (2022). Cryopreservation of induced pluripotent stem cell-derived dopaminergic neurospheres for clinical application. Journal of Parkinson's Disease, 12(3), 871–884. https://doi.org/10.3233/JPD-212934
10. Okumura, N., Kagami, T., Watanabe, K., Kadoya, S., Sato, M., & Koizumi, N. (2019). Feasibility of a cryopreservation of cultured human corneal endothelial cells. PLOS ONE, 14(6), e0218431. https://doi.org/10.1371/journal.pone.0218431
11. Restivo, G., Tastanova, A., Balázs, Z., Panebianco, F., Diepenbruck, M., Ercan, C., Preca, B. T., Hafner, J., Weber, W. P., Kurzeder, C., Vetter, M., Soysal, S. M., Beisel, C., Bentires-Alj, M., Piscuoglio, S., Krauthammer, M., & Levesque, M. P. (2022). Live slow-frozen human tumor tissues viable for 2D, 3D, ex vivo cultures and single-cell RNAseq. Communications Biology, 5(1), 1144. https://doi.org/10.1038/s42003-022-04025-0
12. Jantet-Blaudez, F., Ruiz, J., Gautheron, S., & Pagnon, A. (2025). Evaluation of the viability and functionality of human peripheral blood mononuclear cells cryopreserved up to 2 years in animal-protein-free freezing media compared to the FBS-supplemented reference medium. Frontiers in Immunology, 16, 1627973. https://doi.org/10.3389/fimmu.2025.1627973

+49 2421 55496 0
+49 2421 55496 11
info@nippongenetics.eu
www.nippongenetics.eu